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Prostate cancer is the second leading cause of cancer-related deaths in US males,
yet much remains to be learned about the role of inflammation in its etiology. We
hypothesized that preexisting exposure to chronic inflammatory conditions caused by
infectious agents or inflammatory diseases increase the risk of prostate cancer. Using
the 2009–2010 National Health and Nutrition Examination Survey, we examined the
relationships between demographic variables, inflammation, infection, circulating plasma
C-reactive protein (CRP), and the risk of occurrence of prostate cancer in USmen over 18
years of age. Using IBM SPSS, we performed bivariate and logistic regression analyses
using high CRP values as the dependent variable and five study covariates including
prostate cancer status. From 2009–2010, an estimated 5,448,373 men reported having
prostate cancer of which the majority were Caucasian (70.1%) and were aged 40
years and older (62.7%). Bivariate analyses demonstrated that high CRP was not
associated with an increased risk of prostate cancer. Greater odds of having prostate
cancer were revealed for men that had inflammation related to disease (OR = 1.029, CI
1.029–1.029) and those who were not taking drugs to control inflammation (OR= 1.330,
CI 1.324–1.336). Men who did not have inflammation resulting from non-infectious
diseases had greater odds of not having prostate cancer (OR = 1.031, CI 1.030–1.031).
Logistic regression analysis yielded that men with the highest CRP values had greater
odds of having higher household incomes and lower odds of having received higher
education, being aged 40 years or older, being of a race or ethnicity different from other,
and of having prostate cancer. Our results show that chronic inflammation of multiple
etiologies is a risk factor for prostate cancer and that CRP is not associated with this
increased risk. Further research is needed to elucidate the complex interactions between
inflammation and prostate cancer.
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Introduction
Prostate cancer is a slowly progressive chronic disease that is a
significant health problem for aging males both in the United
States (US) population and worldwide. In the US, prostate
cancer is the most commonly diagnosed non-skin cancer and
the second leading cause of cancer deaths. In 2013 alone, an
estimated 238,590 men were diagnosed with prostate cancer
and 29,720 deaths were associated with this disease (Siegel
et al., 2013). Numerous epigenetic factors and somatic genetic
changes promote the development of prostate cancer (Kim et al.,
2007). Age (Armitage and Doll, 1954, 1957), geographic location
(Goggins and Wong, 2009; Center et al., 2012), family history of
the disease (Kicinski et al., 2011), and race/ethnicity (Merrill and
Sloan, 2012) are well documented risk factors for prostate cancer
that cause wide variation in disease incidence (Crawford, 2003;
Pu et al., 2004) as well as environmental and life-style factors such
as diet and obesity (Hsing and Chokkalingam, 2006). Despite this
information, little is known about the precise factors leading to
the development and progression of prostate cancer. A better
understanding of the factors contributing to prostate cancer
incidence represents an important opportunity to improve health
outcomes of this disease.
Recently, epidemiologic, genetic, and molecular studies
have indicated that prostate cancer may have infectious and
inflammatory origins and furthermore that prostate cancer is not
simply a result of aging (Sutcliffe et al., 2006; De Marzo et al.,
2007; Sciarra et al., 2007; Cheng et al., 2010). Inflammation of the
prostate, known as prostatitis, is a heterogeneous disease in men
that may be symptomatic or asymptomatic, and is characterized
by bacterial or inflammatory causes (Krieger et al., 1999; Nelson
et al., 2013). Some studies have reported a positive association
between prostatic inflammation and prostate cancer, although
these studies had limitations such as potential detection bias
and inaccuracies of self-reporting (Dennis et al., 2002; Roberts
et al., 2004; Palapattu et al., 2005; Patel et al., 2005). Intriguingly,
a causal link has been established for the roles of hepatitis B
and hepatitis C in hepatic cancer (Alison et al., 2011), human
papillomavirus virus (HPV) in cervical cancer (zur Hausen,
1996), Epstein Barr virus (EBV)—a herpes virus—in head and
neck lymphomas (Burkitt, 1958), and HIV infections in an
increased risk of non-Hodgkin lymphoma and Karposi’s sarcoma
(Goedert, 2000). These infectious agents share a common
pathogenesis of long latency after viral exposure and chronic
inflammation is a common component of these virally induced
malignancies. A population based study found that the odds of
prostate cancer were increased in men of African descent who
were infected with the sexually transmitted disease gonorrhea or
who developed prostatitis (Sarma et al., 2006).
C-reactive protein (CRP) is a plasma protein that rises rapidly
in the circulation in response to acute inflammation, infection,
and tissue damage (Gabay and Kushner, 1999; Black et al.,
2004). Blood levels of CRP are also moderately elevated during
chronic inflammatory diseases and cancer (Allin et al., 2009).
CRP is a non-specific marker of inflammation and a positive
association between elevated circulating CRP levels and risk
of cancer of any type has been reported (Allin et al., 2009;
Heikkilä et al., 2011). A few studies indicate that human CRP
is preferentially glycosylated as a post-translational modification
(Köttgen et al., 1992; Das et al., 2003). Glycosylation of CRP
may differ in the carbohydrate and amino-acid sequences
depending on the inducing pathological condition including
infectious, non-infectious, and neoplastic diseases (Das et al.,
2003). The biological function of CRP is strongly dependent on
its structure and isoforms of CRP have been shown to bind to
neoglycoproteins containing simple sugar structures (Lee and
Lee, 2006). Glycosylation of human CRP and its carbohydrate
binding properties under different pathological conditions may
serve as a marker of disease and influence its biological function
in prostate cancer. It is therefore important to further investigate
the relationship between CRP and prostate cancer. Prostatitis
was reported to be a precursor to prostate cancer but elevated
circulating levels of CRP were not predominantly associated
with increased risk of prostate cancer (Platz et al., 2004;
Siemes et al., 2006; De Marzo et al., 2007; Allin et al., 2009;
Heikkilä et al., 2011). In contrast, recent studies have shown
that CRP participates in tumor proliferation and high serum
concentrations of CRP were correlated with shorter overall
survival in patients with castration-refractory prostate cancers
(Beer et al., 2008).
Given this body of evidence, it is plausible to infer that
chronic inflammation resulting from infections or from other
causes may predispose affected men to develop prostate cancer
however a need exists to further examine these relationships. Our
study sought to more clearly define the associations between the
occurrence of infection and inflammation of varied etiologies,
and the incidence of prostate cancer using a large population
based cohort of males in the US. We examined CRP as an
inflammatory indicator of the risk of prostate cancer. We also
investigated the role of non-steroidal anti-inflammatory drugs
(NSAIDS) in these relationships since regular NSAID use is
associated with a modestly reduced risk of prostate cancer
(Nelson and Harris, 2000; Jacobs et al., 2005). In this study, we
hypothesized that preexisting exposure to chronic inflammatory
conditions caused by infectious agents or inflammatory diseases
increase the risk of occurrence of prostate cancer.
Materials and Methods
To answer the research question, 2009–2010 NHANES data
were analyzed. The NHANES is conducted by the Centers
for Disease Control and Prevention’s (CDC)1 National Center
for Health Statistics (NCHS) and is NCHS’ most in-depth
and logistically complex survey. NHANES collects nationally
representative data on the health and nutritional status
of the non-institutionalized, civilian population of the US.
To collect these data the survey employs a stratified and
multistage probability sampling design. There are two parts
to the NHANES. The first part entails collecting data using
a standardized personal/household interview protocol. For the
1Centers for Disease Control and Prevention. About the National Health and
Nutrition Examination Survey (NHANES) available at www.cdc.gov/nchs/about/
major/nhanes/intro_mec.htm. Accessed on May 13, 2013.
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second part of NHANES, standardized physical examinations,
diagnostic procedures, and laboratory tests of biologic samples
are undertaken at mobile examination trailers. These dual
data collection techniques and efforts are used to obtain
information about diagnosed and undiagnosed conditions;
growth and development, including overweight and obesity; diet
and nutrition; risk factors; and environmental exposures. While
NHANES data have been collected since the early 1960s, in 1999,
the survey became a continuous yet nimble endeavor allowing for
changing foci on a variety of health and nutrition measurements
to meet emerging needs.
To ensure national representativeness, the NCHS and CDC
recommend that all analyses of NHANES data be conducted on
weighted data. The weighting of sample data permits analysts
to produce estimates of the statistics that would have been
obtained if the entire sampling frame had been surveyed. Sample
weights can be considered as measures of the number of
persons represented by the particular sampled participant. A
more detailed explanation of the survey design for the NHANES,
including approval from the CDC institutional review board for
data collection and analysis, is available elsewhere1.
Four demographic variables were included in the analyses
performed. They were race/ethnicity, age, education, and annual
household income. For analysis purposes, these variables were
all recoded from their original format. Recoding the variables
entailed reducing categories (race/ethnicity, household income,
and education) or transforming the variable from a continuous
to a categorical one (age). For all of the demographic variables
the categories of “don’t know” and “refused” were removed.
Four inflammation proxy variables were used in the analyses
performed. These were: circulating plasma CRP (high grade
inflammation was defined as CRP values >3mg/ml and low
grade inflammation as CRP values of ≤3mg/ml); inflammation
due to infection; drug use to control inflammation; and
inflammation resulting from existing disease. The last three of
these four variables were computed from multiple variables as
indicated in the Chart 1 below.
CHART 1 | Computed variables with contributing variables, NHANES
2009–2010.
Computed variable Contributing variable
Inflammation from infection Positive result for Epstein Barr virus
Positive result for HIV antibody
Positive result for Hepatitis B core
antibody
Positive result for Hepatitis B surface
antigen
Positive result for Hepatitis C antibody
(confirmed)
Positive result for Hepatitis C RNA
(HCV-RNA)
Positive result for Herpes Simplex Virus I
Positive result for Herpes Simplex Virus II
(Continued)
CHART 1 | Continued
Computed variable Contributing variable
Inflammation indicated from drugs Take prednisone or cortisone daily
Taken ibuprofen for pain
Taken naproxyn for pain
Taken indomethacin for pain
Taken cox-2 inhibitor for pain
Taken aspirin for pain
Inflammation indicated from disease Have osteoporosis/brittle bones
Have diabetes
Have arthritis
Have congestive heart failure
Have coronary heart disease
Have angina/angina pectoris
Have had a heart attack
Two bivariate analyses were performed. The first to describe
the study population by prostate cancer status (have prostate
cancer vs. did not have prostate cancer); the second, to
examine the unadjusted relationship between the dependent
variable (Prostate Cancer Status) by the computed inflammation
covariates. One logistic regression model was tested with High
Cancer Risk C-Reactive Protein Value as the dependent variable
with five study covariates entered into the model. In the logistic
regression analysis, prostate cancer status was entered into the
model as a covariate.
Alpha was set at 0.05 for all tests of statistical significance.
SPSS version 22.0 (IBM, Chicago, IL) was used to complete
the analyses. The Institutional Review Board (IRB) at the
researchers’ institution recognize that the analysis of de-identified
and publicly available data does not constitute human subjects
research as defined in federal regulations and as such does not
require IRB review. Hence, human subjects’ approval was not
necessary nor sought since this was a de-identified data only
study.
Results
Table 1 displays the bivariate analysis result of five of the study
covariates by the dependent variable prostate cancer status. The
population included in this analysis was men 18 years of age
and older for the 2009–2010 NHANES survey. An estimated
296,495,347 men reported having no prostate cancer while
5,448,373 reported having prostate cancer. Of those men with
prostate cancer, 70.1% were Caucasian, 13.5% were African
American or Black, 13.4%were Hispanic, and 3.1% reported their
race to be “Other” including multiracial status. The majority of
men aged 40 years and older (62.7%) reported having prostate
cancer. While all the differences between men with and without
prostate cancer were statistically significant, this is not surprising
since the analyses were performed on large sample weighted data.
Table 2 displays the study’s four inflammation related
variables by prostate cancer status. For CRP, men with a low risk
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TABLE 1 | Description of study population by prostate cancer status, 2009–2010 NHANES data.
Variables and factors % Prostate cancer status P (for z-test)
No prostate cancer (n = 296495347)* Has prostate cancer (n = 5448373)*
Race/Ethnicity Hispanic 16.0 13.4 <0.05
Caucasian 64.5 70.1 <0.05
African American or Black 12.0 13.5 <0.05
Other 7.5 3.1 <0.05
Age 18–39 years 39.1 37.3 <0.05
40 and older 60.9 62.7 <0.05
Education <HS 18.9 26.4 <0.05
HS graduate 53.4 48.3 <0.05
University graduate 27.7 25.3 <0.05
Annual household income <$54,999 48.1 52.8 <0.05
≥$55,000–99,999 29.7 23.1 <0.05
$100,000 and over 22.1 24.1 <0.05
C-reactive protein Low risk for cancer 43.1 39.9 <0.05
No cancer risk 28.6 32.9 <0.05
High risk for cancer 28.4 27.2 <0.05
*Weighted; HS, High School.
TABLE 2 | Inflammation covariates by prostate cancer status, 2009–2010 NHANES data.
Variables and factors Percent by prostate cancer status Unadjusted odds ratios (%95 CI)
No prostate cancer Has prostate cancer
C-reactive protein Low grade inflammation (≤3mg/ml) 71.6 72.8 OR = 1.061 (1.059–1.064) Men with low
grade inflammation by CRP measure had
slightly higher odds of having prostate
cancerHigh grade inflammation (>3mg/ml) 28.4 27.2
Inflammation from infection No inflammation from infection 68.9 35.0 OR = 1.029 (1.029–1.029) Men with no
inflammation from infection had slightly
greater odds of not having prostate cancerInflammation from infection 31.1 65.0
Drug use to control inflammation No drugs taken for inflammation 14.6 18.7 OR = 1.330 (1.324–1.336) Men who were
not taking drugs to control inflammation
had greater odds of having prostate
cancerDrugs taken for inflammation 85.4 81.3
Existing disease causing inflammation No disease causing inflammation 63.4 54.0 OR = 1.031 (1.030–1.031) Men with no
inflammation from disease had greater
odds of not having prostate cancerDisease causing inflammation 36.6 46.0
of cancer by CRP measure had slightly higher odds of having
prostate cancer. When examining the relationship between
inflammation from infection and prostate cancer status, men that
did not have diseases such as EBV, HIV, hepatitis B and C, and
HSV I and II that are associated with inflammation had slightly
greater odds of not having prostate cancer. The analysis of men
taking anti-inflammatory drugs for a presumed inflammatory
condition by prostate cancer status revealed that men that were
not taking anti-inflammatory drugs had greater odds of having
prostate cancer. Finally, the computed variable of inflammation
indicated from inflammatory diseases by prostate cancer status
indicated that men without disease-related inflammation had
greater odds of not having prostate cancer.
For the logistic regression analysis performed, prostate
cancer was entered into the model as a covariate along with
race/ethnicity, annual household income, education, and age
(Table 3). The category of high CRP values was the dependent
variable in this model. Analysis yielded that men with the
highest CRP values had greater odds of having higher household
incomes. These men with high CRP values had lower odds of
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TABLE 3 | Logistic regression with high grade (>3mg/ml) inflammation
C-reactive protein values as the dependent variable 2008–2009 NHANES
data.
Variables Factors Adjusted odds ratios (95% CI)
Race/Ethnicity Hispanic 0.818 (0.817, 0.819)
Caucasian 0.961 (0.960, 0.963)
African American
or Black
0.906 (0.904, 0.907)
Other *–
Annual household income <$54,999 *–
≥$55,000–99,999 1.106 (1.105, 1.107)
$100,000 and
over
1.122 (1.121, 1.123)
Education <HS *–
HS graduate 0.761 (0.761, 0.762)
University
graduate
0.804 (0.803, 0.805)
Age 18–39 years *–
40 and older 0.919 (0.919, 0.920)
Prostate cancer No prostate
cancer
*–
Prostate cancer 0.854 (0.852, 0.856)
having received higher education, being aged 40 years or older,
being of a race or ethnicity different from other, and of having
prostate cancer.
Discussion
Evidence from histopathologic, molecular, and epidemiologic
studies indicates that prostatic inflammation plays a vital role in
the development of prostate cancer (Nelson et al., 2004; Pollard,
2004; Balkwill et al., 2005; De Marzo et al., 2007). Several studies
on the association between levels of the inflammatory marker
CRP and risk of prostate cancer have reported negative results
however these studies used small sample sizes in case-controlled
study designs (Platz et al., 2004; Siemes et al., 2006; De Marzo
et al., 2007; Allin et al., 2009; Heikkilä et al., 2011). Using 2009–
2010NHANES data, we sought to study the potential associations
between inflammation and the occurrence of prostate cancer
further by using the inflammatorymarker CRP and by employing
a large sample size of over 5 million men of different races and
economic backgrounds who were 18 years of age or older.
In agreement with the previously mentioned reports, we
found that CRP was not a reliable indicator of risk of prostate
cancer as men with CRP values ≤3mg/ml (low levels of
inflammation) had slightly higher odds of having prostate cancer.
In support of our hypothesis that inflammation related to
infection and other causes increased the risk of occurrence
of prostate cancer, we observed that infection with EBV, HIV,
Hepatitis B or C, or HSV I or II and the corresponding
inflammation associated with these diseases increased the risk of
occurrence of prostate cancer. Similarly, those men who reported
having inflammatory diseases such as osteoporosis, diabetes
mellitus, arthritis, or cardiovascular diseases were at a greater
risk of having prostate cancer. Several epidemiological studies
have found an increased risk of prostate cancer in association
with a history of prostatitis (Dennis et al., 2002; Roberts
et al., 2004; Patel et al., 2005) or infection with any sexually
transmitted diseases (STD) including syphilis, gonorrhea, and
human papilloma virus (Dennis and Dawson, 2002; Patel et al.,
2005). Limitations of many of these studies were the inclusion of
primarily Caucasian men or populations in which the prevalence
of prostate cancer and/or STDs was low, or small sample
sizes. We add novel information to existing knowledge by
using a large population-based sample size to demonstrate that
chronic inflammation from multiple etiologies including some
viral infections (sexually and non-sexually transmitted) and the
existence of non-infectious inflammatory diseases are risk factors
for prostate cancer.
We observed that men who were taking NSAIDS were at
a lower risk of having prostate cancer. Several epidemiological
studies examining the association between the use of NSAIDs
and the risk of prostate cancer suggest an inverse relationship
however reports are inconsistent (Nakai and Nonomura,
2013). These discrepancies may be due to differences in
doses and duration of treatment, and screening bias by
healthcare providers. In our study, NSAID use was self-
reported and we included men with any previous history of
taking NSAIDS.
Age (Armitage and Doll, 1954, 1957), geographic location
(Goggins and Wong, 2009; Center et al., 2012), family history
of the disease (Kicinski et al., 2011), and race/ethnicity (Merrill
and Sloan, 2012) are well-established risk factors for prostate
cancer. In our study, we performed logistic regression analysis
using high levels of CRP (>3mg/ml indicating increased risk
of any type of cancer) as the dependent variable. We found
that high CRP values indicating high inflammation were not
positively correlated with the occurrence of prostate cancer.
Other variables in the logistic regression model (race/ethnicity,
annual household income, education, and age) were used to
control for confounding effects between the variables of high
CRP values (the dependent variable) and prostate cancer (the
independent variable). Our finding that men with the highest
CRP values indicating highest cancer risk had greater odds of
having higher household incomes is in agreement with some
studies (Rimpela and Pukkala, 1987; Yu et al., 1988), but
inconsistent with others (Oishi et al., 1989; Fincham et al., 1990)
and a few studies have reported no association (Talamini et al.,
1986; Severson et al., 1989). Possible reasons for our finding
are that men with higher household incomes may have greater
medical attention, easier access to higher quality healthcare, and
different attitudes and concern over health matters than men
with lower household incomes.
The limitations of our study were mostly attributable to how
the survey data were collected. First, the NHANES database is a
cross-sectional survey of the U.S. population and therefore does
not have longitudinal relationships with participants. Since the
information is from self-reported data, wemay not have captured
all actual cases of prostate cancer. Second, we could only examine
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covariates that were available from the 2009–2010 NHANES
because the data pertaining to our study was not consistently
available and reported for all years. For this reason, we could
not estimate the prevalence of prostate cancer. Third, we were
not able to obtain information on mortality and the geographic
distribution of respondents as this information is not collected
from NHANES.
Despite these limitations, our study had strengths worth
noting. Since we used national patient record population-level
survey data, we had a large data set that was weighted to
ensure that our findings could be more easily and accurately
generalized to the US population. Our pilot study demonstrated
that NHANES can be used to examine relationships between
CRP, demographic variables, inflammation, and prostate cancer.
Chronic inflammation resulting from infectious or non-
infectious diseases can increase the risk of having prostate cancer.
Men with a higher household income are at a higher risk of
having prostate cancer. Future studies will be needed in order to
elucidate the complex relationships between inflammation and
prostate cancer to be able to develop novel strategies to target the
inflammatory process and combat this malignancy.
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